Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Genesis Research LLC

Neither a doctor nor a teaching hospital

Research payments

$10,249,875

191 payments

Through program year 2025, Genesis Research LLC is reported as receiving $10,249,875 in research payments, across 191 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $1,729,172 69
2024 Research $2,576,457 75
2023 Research $2,485,059 23
2022 Research $2,706,873 22
2021 Research $752,314 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $7,182,286 16 payments
  2. Janssen Research & Development, LLC $1,814,367 108 payments
  3. AstraZeneca Pharmaceuticals LP $510,076 2 payments
  4. Sumitomo Pharma America, Inc. $213,013 26 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $175,631 12 payments
  6. Veru Inc. $159,778 18 payments
  7. Dendreon Pharmaceuticals LLC $143,938 3 payments
  8. Ortho-Clinical Diagnostics, Inc. $27,408 3 payments
  9. Endo Pharmaceuticals Inc. $20,379 2 payments
  10. Boston Scientific Corporation $3,000 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 $5,617,567 10 payments
  2. A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc $994,218 48 payments
  3. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 $934,016 3 payments
  4. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i $591,333 1 payment
  5. a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco $510,076 2 payments
  6. MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM $319,051 20 payments
  7. A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc $237,778 14 payments
  8. ProvONE Study $139,846 2 payments
  9. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $114,956 12 payments
  10. Veracity - Randomized, Active-Controlled, Phase 3 Study of Veru-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent $107,295 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record